Tom Mulder

Mr. Tom Mulder

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TMTom Mulder
Tom Mulder
BWBjörn E. Wahlin
Björn E. Wahlin
AÖAnders Österborg
Anders Österborg
MPMarzia Palma
Marzia Palma
In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor microenvironment (TME). The features of the TME differ between the different lymphoma types, ranging from extremely inflammatory, such as in Hodgkin lymphoma, to anergic, leading to immune deficiency and susceptibility to infections, such as in chronic lymphocytic leukemia. Understanding the characteristic features of the TME as well as the interactions between cancer and TME cells has given insight into the pathogenesis of most lymphomas and contributed to identify novel therapeutic targets. Here, we summarize the preclinical data that contributed to clarifying the role of the immune cells in the TME of different types of lymphomas of B-cell origin, and explain how the understanding of the biological background has led to new clinical applications. Moreover, we provide an overview of the clinical results of trials that assessed the safety and efficacy of drugs directly targeting TME immune cells in lymphoma patients.

23 March 2018 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MPMarzia Palma
Marzia Palma
LHLotta Hansson
Lotta Hansson
TMTom Mulder
Tom Mulder
LALars Adamson
Lars Adamson
BNBarbro Näsman‐Glaser
Barbro Näsman‐Glaser
HMHåkan mellstedt
Håkan mellstedt

13 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
WZWen Zhong
Wen Zhong
PKParviz Kokhaei
Parviz Kokhaei
TMTom Mulder
Tom Mulder
AGAmineh Ghaderi
Amineh Ghaderi
AMAli Moshfegh
Ali Moshfegh
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
Background/Objectives: Nurse-like cells (NLCs) derived from monocytes in the tumor microenvironment support the growth of chronic lymphocytic leukemia (CLL) cells. Here, we investigated the effects of a CX3CR1 (fractalkine receptor) antagonist (KAND567) on autologous monocytes and their pro-survival effects on CLL cells in vitro. Methods: Plasma concentration of CX3CL1 was determined by ELISA and CX3CR1 expression by flow cytometry. CD19+ cells and autologous monocytes from patients with CLL and healthy donors were treated with KAND567 either in co-culture or alone. The apoptosis of CD19+ cells and monocytes was determined by Annexin V/PI staining and live-cell imaging. Results: Plasma concentration of CX3CL1 (fractalkine) was significantly higher in patients with CLL (n = 88) than in healthy donors (n = 32) (p < 0.0001), with higher levels in patients with active compared to non-active disease (p < 0.01). CX3CR1 was found on monocytes but not B cells in patients and controls. Levels of intermediate and non-classical CX3CR1+ monocytes were higher in patients with CLL than in controls (p < 0.001), particularly in those with active disease (p < 0.0001). Co-culture experiments revealed that autologous monocytes promoted the survival of both malignant and normal B cells and that KAND567 selectively inhibited the growth of CLL cells in a dose-dependent manner but only in the presence of autologous monocytes (p < 0.05). Additionally, KAND567 inhibited the transition of monocytes to NLCs in CLL (p < 0.05). Conclusions: Our data suggest that the CX3CR1/CX3CL1 axis is activated in CLL and may contribute to the NLC-driven growth-promoting effects of CLL cells. KAND567, which is in clinical trials in other disorders, should also be explored in CLL.

14 July 2021 in eJHaem
Verified
Journal Article
Open access
PDF file
JLJeanette Lundin
Jeanette Lundin
TMTom Mulder
Tom Mulder
MKMagdalena Kättström
Magdalena Kättström
TWTove Wästerlid
Tove Wästerlid
AUAnders Uddevik
Anders Uddevik
AÖAnders Österborg
Anders Österborg
Ibrutinib is used continuously in CLL. This phase 1b/2 study interim analysis explored on-off-repeat dosing to reduce toxicity. After 12 months, 16/22 patients (73%) remained in first off-phase irrespective if initial CR/PR or TP53 aberration. Grade 3-4 infections were reduced from 55% to 5% during a similarly long off-phase (P < .01). Treg and exhausted T-cells increased (P = .01). Six patients restarted ibrutinib at early progression and remain drug-sensitive. Our interim analysis shows a durable off-phase in most patients, with reduced infections and cost-saving potential. If toxicity-driven permanent cessation of ibrutinib will be affected will be explored in the extended study.

15 February 2024 in Blood Neoplasia
Verified
Journal Article
Open access
AMAgnes Mattsson
Agnes Mattsson
JLJeanette Lundin
Jeanette Lundin
TMTom Mulder
Tom Mulder
SSSandra E. Sylvan
Sandra E. Sylvan
MPMarzia Palma
Marzia Palma
AÖAnders Österborg
Anders Österborg

25 December 2025 in British Journal of Haematology
Verified
Journal Article
Open access
MAMaria L. Andersson
Maria L. Andersson
OLOlina Lind
Olina Lind
KHKia Heimersson
Kia Heimersson
ABAnna Berglöf
Anna Berglöf
TSTeresa del Peso Santos
Teresa del Peso Santos
MPMarzia Palma
Marzia Palma